DOI
https://doi.org/10.18849/ve.v6i3.412Abstract
PICO question
In dogs with hyperadrenocorticism that are being treated with trilostane, does the measurement of basal cortisol levels have comparable diagnostic performance to the adrenocorticotropic hormone (ACTH) stimulation test?
Clinical bottom line
Category of research question
Diagnosis (effectiveness of treatment monitoring)
The number and type of study designs reviewed
Four cross-sectional diagnostic accuracy studies were critically reviewed
Strength of evidence
Weak to moderate (level 2)
Outcomes reported
There is evidence of moderate strength suggesting that basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane can be a good test to exclude adrenal oversuppression, while its use is not suggested for diagnostic confirmation of oversuppression. There is evidence of weak strength that basal cortisol might be helpful for identifying dogs with inadequate adrenal suppression, but cannot be used to rule it out
Conclusion
Although the evaluation of the available evidence is difficult due to its heterogeneity, there is moderate evidence that a basal cortisol measured at 4–6 hours (and possibly 2–3 hours) post-trilostane dose can be a good test to rule out adrenal oversuppression, but that it cannot be used to definitively diagnose oversuppression. The current evidence suggests that basal cortisol is less useful for identification of inadequate control. Based on one included study, neither ACTH-stimulated nor basal cortisol levels correlate optimally with the actual clinical response of the patient. In this context, it can be concluded that none of the currently used laboratory tests should be used as a sole monitoring tool in dogs with hyperadrenocorticism receiving trilostane and thus, the assessment of the clinical response is of utmost importance
How to apply this evidence in practice
The application of evidence into practice should take into account multiple factors, not limited to: individual clinical expertise, patient’s circumstances and owners’ values, country, location or clinic where you work, the individual case in front of you, the availability of therapies and resources.
Knowledge Summaries are a resource to help reinforce or inform decision making. They do not override the responsibility or judgement of the practitioner to do what is best for the animal in their care.
References
Alenza, D.P., Arenas, C., Lopez, M.L. & Melian, C. (2006). Long-Term Efficacy of Trilostane Administered Twice Daily in Dogs With Pituitary-Dependent Hyperadrenocorticism. Journal of the American Animal Hospital Association. 42(4), 269–276. DOI: http://dx.doi.org/10.5326/0420269
Arenas Bermejo, C.A., Alenza, D.P., San José, P.G., Llauet, L., Pérez‐López, L., Melián, C. & Feldman, E.C. (2020). Laboratory assessment of trilostane treatment in dogs with pituitary‐dependent hyperadrenocorticism. Journal of Veterinary Internal Medicine.34(4), 1413–1422. DOI: https://doi.org/10.1111/jvim.15830
Balshem, H., Helfand, M., Schunemann, H.J., Oxman, A.D., Kunz, R., Brozek, J., Vist, G.E., Falck‐Ytter, Y., Meerpohl, J., Norris, S. & Guyatt, G.H. (2011). GRADE guidelines: 3. Rating the quality of evidence. Journal of Clinical Epidemiology. 64(4), 401–406. DOI: https://doi.org/10.1016/j.jclinepi.2010.07.015
Behrend, E. (2015). Canine hyperadrenocorticism. In: E. Feldman, R. Nelson, C. Reusch & J. Scott-Moncrieff, ed., Canine and Feline Endocrinology, 4th St Louis: Elsevier, 377–451.
Bonadio, C.M., Feldman, E.C., Cohen, T.A. & Kass, P.H. (2014). Comparison of Adrenocorticotropic Hormone Stimulation Test Results Started 2 versus 4 Hours after Trilostane Administration in Dogs with Naturally Occurring Hyperadrenocorticism. Journal of Veterinary Internal Medicine. 28(4), 1239–1243. DOI: http://dx.doi.org/10.1111/jvim.12357
Boretti, F.S., Holzthuem, J., Reusch, C.E. & Sieber-Ruckstuhl, N.S. (2016). Lack of association between clinical signs and laboratory parameters in dogs with hyperadrenocorticism before and during trilostane treatment. Schweizer Archiv für Tierheilkunde. 158(9), 631–638. DOI: http://dx.doi.org/10.17236/sat00083
Burkhardt, W.A., Boretti, F.S., Reusch, C.E. & Sieber‐Ruckstuhl, N.S. (2013). Evaluation of Baseline Cortisol, Endogenous ACTH, and Cortisol/ACTH Ratio to Monitor Trilostane Treatment in Dogs with Pituitary‐Dependent Hypercortisolism. Journal of Veterinary Internal Medicine. 27(4), 919–923. DOI: http://dx.doi.org/10.1111/jvim.12111
Cook, A.K. & Bond, K.G. (2010). Evaluation of the use of baseline cortisol concentration as a monitoring tool for dogs receiving trilostane as a treatment for hyperadrenocorticism. Journal of the American Veterinary Medical Association. 237(7), 801–805. DOI: http://dx.doi.org/10.2460/javma.237.7.801
Lemetayer, J. & Blois, S. (2018). Update on the use of trilostane in dogs. The Canadian Veterinary Journal. 59(4), 397–407. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5855282/ [Accessed 20/04/2021]
Macfarlane, L., Parkin, T. & Ramsey, I. (2016). Pre-trilostane and three-hour post-trilostane cortisol to monitor trilostane therapy in dogs. Veterinary Record. 179(23), 597. DOI: http://dx.doi.org/10.1136/vr.103744
Ramsey, I.K. (2010). Trilostane in dogs. Veterinary Clinics of North America: Small Animal. 40(2), 269–83. DOI: http://dx.doi.org/10.1016/j.cvsm.2009.10.008
Wehner, A., Gloeckner, S., Sauter-Louis, C., Kruse, D., Stockhaus, C. & Hartmann, K. (2013). Association between ACTH stimulation test, clinical signs, and laboratory parameters in dogs with hyperadrenocorticism treated with trilostane. Journal of Veterinary Internal Medicine. 28, DOI: http://dx.doi.org/10.1111/jvim.12278
Whiting, P.F., Rutjes, A.W., Westwood, M.E., Mallett, S., Deeks, J.J., Reitsma, J.B., Leeflang, M.M.G., Sterne, J.A.C., Bossuyt, P.M. & the QUADAS-2 Group. (2011). QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy Studies. Annals of Internal Medicine. 155, 529–536. DOI: http://dx.doi.org/10.7326/0003-4819-155-8-201110180-00009
Woolcock, A.D., Bugbee, A.C. & Creevy, K.E. (2016). Evaluation of baseline cortisol concentration to monitor efficacy of twice-daily administration of trilostane to dogs with pituitary-dependent hyperadrenocorticism: 22 cases (2008–2012). Journal of the American Veterinary Medical Association. 248(7), 814–821. DOI: http://dx.doi.org/10.2460/javma.248.7.814
License
Copyright (c) 2021 Dr Tsouloufi, Ioannis Oikonomidis
This work is licensed under a Creative Commons Attribution 4.0 International License.
Veterinary Evidence uses the Creative Commons copyright Creative Commons Attribution 4.0 International License. That means users are free to copy and redistribute the material in any medium or format. Remix, transform, and build upon the material for any purpose, even commercially - with the appropriate citation.
Most read articles by the same author(s)
- Ioannis L. Oikonomidis, Theodora K. Tsouloufi, Diagnostic accuracy of cytology for canine osteosarcoma compared to histopathology , Veterinary Evidence: Vol. 6 No. 2 (2021): The second issue of 2021
